<p><strong>Immix Biopharma Inc</strong> (NASDAQ: IMMX) 的股票在周一早晨略微下跌，此前该临床阶段生物技术公司向美国证券交易委员会提交了一份新的 S-3 表格的货架注册声明。</p>
<p>该注册声明将允许公司不时提供和出售高达 7.5 亿美元的普通股、优先股、债务证券、认股权证和单位。</p>
<ul>
<li>Immix Biopharma 股票面临卖压。为什么 IMMX 股票下跌？</li>
</ul>
<h3>新的 7.5 亿美元 IMMX 货架替代 2023 年注册</h3>
<p>最新的 S-3 结构为根据 SEC 规则 415(a)(6) 的替代货架，延续了 2023 年 1 月生效的先前注册中未售出的证券。</p>
<p>根据新的货架注册，Immix 可以有机会进入资本市场，未来任何发行的具体条款和定价将在后续的招股说明书补充中详细说明。</p>
<h3>收益将用于资助 AL 淀粉样变 CAR-T 管线</h3>
<p>Immix Biopharma 计划将净收益主要用于营运资金和一般企业用途，这可能包括推进其主要 CAR-T 候选药物 NXC-201 用于 AL 淀粉样变和其他严重疾病。</p>
<p>该公司还强调了标准风险因素和前瞻性声明披露，提醒投资者，任何未来在货架下的股权发行可能会稀释现有股东的权益。</p>
<p><strong>Benzinga Edge 排名：</strong> Benzinga Edge 的 专有排名显示，Immix Biopharma 的动量得分为 96.03，得益于积极的短期、中期和长期价格趋势。</p>
<p><img src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/01/12100025/Screen-Shot-2026-01-12-at-9.59.57-AM-1024x207.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/01/12100025/Screen-Shot-2026-01-12-at-9.59.57-AM-1024x207.png"/></p>
<p><strong>IMMX 价格走势：</strong> 根据 Benzinga Pro 的数据，Immix Biopharma 的股票在周一发布时下跌了 4.11%，报 4.67 美元。</p>
<h2>Immix Biopharma 能否突破 5 美元关口？</h2>
<p>该股票的 52 周范围为 1.34 美元至 7.73 美元，突显了其波动性和显著的价格波动潜力。目前，价格远高于该范围的下限，这可能为希望进入或增加持仓的投资者提供心理支撑位。</p>
<p>在 5.00 美元附近可能会遇到阻力，卖方可能会出现以利用任何上行动能。如果股票能够突破这一阻力，可能为测试更高水平铺平道路，潜在接近最近的高点 7.73 美元。</p>
<p>对 Immix Biopharma 的整体技术前景保持谨慎乐观，因为该股票的交易价格远高于历史低点。持续监测成交量和价格走势将对评估任何潜在反弹或近期进一步下跌的力度至关重要。</p>
<p><em>图片来源：Shutterstock</em></p>

IMMX

<p>Immix Biopharma Inc（纳斯达克代码：IMMX）股价下跌 4.11%，至 4.67 美元，此前该公司提交了一份新的货架注册声明，计划发行和出售最多 7.5 亿美元的证券。该文件允许 Immix 有机会进入资本市场，主要用于资助其针对 AL 淀粉样变的 CAR-T 管线。该股票的 52 周区间为 1.34 美元至 7.73 美元，显示出波动性，阻力位约在 5.00 美元。技术前景保持谨慎乐观，但投资者应密切关注成交量和价格走势</p>

<p><strong>Immix Biopharma Inc</strong> (NASDAQ: IMMX) shares are trading marginally lower Monday morning after the clinical-stage biotech filed a new shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission.</p>
<div class="lb-trans"><p><strong>Immix Biopharma Inc</strong> (NASDAQ: IMMX) 的股票在周一早晨略微下跌，此前该临床阶段生物技术公司向美国证券交易委员会提交了一份新的 S-3 表格的货架注册声明。</p>
</div><p>The filing would allow the company to offer and sell up to $750 million of common stock, preferred stock, debt securities, warrants and units from time to time.</p>
<div class="lb-trans"><p>该注册声明将允许公司不时提供和出售高达 7.5 亿美元的普通股、优先股、债务证券、认股权证和单位。</p>
</div><ul>
<li>Immix Biopharma stock is under selling pressure. Why is IMMX stock retreating?</li>
</ul>
<div class="lb-trans"><ul>
<li>Immix Biopharma 股票面临卖压。为什么 IMMX 股票下跌？</li>
</ul>
</div><h3>New $750 Million IMMX Shelf Replaces 2023 Registration</h3>
<div class="lb-trans"><h3>新的 7.5 亿美元 IMMX 货架替代 2023 年注册</h3>
</div><p>The latest S-3 is structured as a replacement shelf under SEC Rule 415(a)(6), carrying forward unsold securities from a prior registration that was declared effective in January 2023.</p>
<div class="lb-trans"><p>最新的 S-3 结构为根据 SEC 规则 415(a)(6) 的替代货架，延续了 2023 年 1 月生效的先前注册中未售出的证券。</p>
</div><p>Under the new shelf registration, Immix can access the capital markets opportunistically, with specific terms and pricing of any future offerings to be detailed in subsequent prospectus supplements.</p>
<div class="lb-trans"><p>根据新的货架注册，Immix 可以有机会进入资本市场，未来任何发行的具体条款和定价将在后续的招股说明书补充中详细说明。</p>
</div><h3>Proceeds to Fund CAR-T Pipeline in AL Amyloidosis</h3>
<div class="lb-trans"><h3>收益将用于资助 AL 淀粉样变 CAR-T 管线</h3>
</div><p>Immix Biopharma plans to use net proceeds primarily for working capital and general corporate purposes, which may include advancing its lead CAR-T candidate NXC-201 for AL amyloidosis and other serious diseases.</p>
<div class="lb-trans"><p>Immix Biopharma 计划将净收益主要用于营运资金和一般企业用途，这可能包括推进其主要 CAR-T 候选药物 NXC-201 用于 AL 淀粉样变和其他严重疾病。</p>
</div><p>The company also highlighted standard risk factors and forward-looking statement disclosures, reminding investors that any future equity issuance under the shelf could dilute existing shareholders.</p>
<div class="lb-trans"><p>该公司还强调了标准风险因素和前瞻性声明披露，提醒投资者，任何未来在货架下的股权发行可能会稀释现有股东的权益。</p>
</div><p><strong>Benzinga Edge Rankings:</strong> Benzinga Edge's proprietary rankings show Immix Biopharma with a strong Momentum score of 96.03, supported by positive short-, medium- and long-term price trends.</p>
<div class="lb-trans"><p><strong>Benzinga Edge 排名：</strong> Benzinga Edge 的 专有排名显示，Immix Biopharma 的动量得分为 96.03，得益于积极的短期、中期和长期价格趋势。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/01/12100025/Screen-Shot-2026-01-12-at-9.59.57-AM-1024x207.png" alt="" original-src="https://editorial-assets.benzinga.com/wp-content/uploads/2026/01/12100025/Screen-Shot-2026-01-12-at-9.59.57-AM-1024x207.png"/></p>
<p><strong>IMMX Price Action:</strong> Immix Biopharma shares were down 4.11% at $4.67 at the time of publication on Monday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>IMMX 价格走势：</strong> 根据 Benzinga Pro 的数据，Immix Biopharma 的股票在周一发布时下跌了 4.11%，报 4.67 美元。</p>
</div><h2>Can Immix Biopharma Break The $5 Barrier?</h2>
<div class="lb-trans"><h2>Immix Biopharma 能否突破 5 美元关口？</h2>
</div><p>The stock’s 52-week range of $1.34 to $7.73 highlights its volatility and potential for significant price swings. Currently, the price is well above the lower end of this range, which may provide a psychological support level for investors looking to enter or add to their positions.</p>
<div class="lb-trans"><p>该股票的 52 周范围为 1.34 美元至 7.73 美元，突显了其波动性和显著的价格波动潜力。目前，价格远高于该范围的下限，这可能为希望进入或增加持仓的投资者提供心理支撑位。</p>
</div><p>Resistance is likely to be encountered around the $5.00 mark, where sellers may emerge to capitalize on any upward momentum. Should the stock manage to break through this resistance, it could pave the way for a test of higher levels, potentially approaching the recent highs near $7.73.</p>
<div class="lb-trans"><p>在 5.00 美元附近可能会遇到阻力，卖方可能会出现以利用任何上行动能。如果股票能够突破这一阻力，可能为测试更高水平铺平道路，潜在接近最近的高点 7.73 美元。</p>
</div><p>The overall technical outlook for Immix Biopharma remains cautiously optimistic, as the stock is trading well above its historical lows. Continued monitoring of volume and price action will be essential to gauge the strength of any potential recovery or further declines in the near term.</p>
<div class="lb-trans"><p>对 Immix Biopharma 的整体技术前景保持谨慎乐观，因为该股票的交易价格远高于历史低点。持续监测成交量和价格走势将对评估任何潜在反弹或近期进一步下跌的力度至关重要。</p>
</div><p><em>Image: Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源：Shutterstock</em></p>
</div>

Immix Biopharma (IMMX) 股价下跌，因投资者关注其计划发行和出售 7.5 亿美元的证券